Mediators of Systemic Inflammatory Response Syndrome and the Role of Recombinant Activated Protein C in Sepsis Syndrome

Infectious Disease Clinics of North America

Volumn 25, Issue 4, 2011, Pages 835-850

  Kak, Vivek ^a  

^a NONE   (United States)

Author keywords

Activated protein C; Sepsis; Sepsis mediators

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR; CD14 ANTIGEN; COMPLEMENT COMPONENT C5A; DROTRECOGIN; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PLACEBO; PROTEINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; CHEMOKINESIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MEDIATOR RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 80455176667     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.07.009     Document Type: Review

References (101)

1. Bone R., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101:1644-1655.
2. Pittet D., Thievent B., Wenzel R.P., et al. Bedside prediction of mortality from bacteremic sepsis, a dynamic analysis of ICU patients. Am J Respir Crit Care Med 1996, 153:684-693.
3. Salvo I., Decain W., Musicco M., et al. The Italian Sepsis Study, preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 1995, 21(Suppl 2):S244-S249.
4. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
5. Webb S.A., Pettila V., Seppelt I., et al. ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009, 361(20):1925-1934.
6. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348(2):138-150.
7. Remick D.G. Pathophysiology of sepsis. Am J Pathol 2007, 170:1435-1444.
8. Sriskandan S., Altmann D.M. The immunology of sepsis. J Pathol 2008, 214:211-223.
9. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3:710-720.
10. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol 2004, 41:1089-1098.
11. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787.
12. Van Amersfoort E.S., Van Berkel T.J., Kuiper J. Receptors, mediators and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003, 16(3):379-414.
13. Inohara C., McDonald C., Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005, 74:355-383.
14. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
15. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998, 282:2085-2088.
16. Ulevitch R.J., Tobias P.S. Receptor-dependent mechanisms of cell stimulation by endotoxin. Annu Rev Immunol 1995, 13:437-457.
17. Takeuchi O., Hoshino K., Kawai T., et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram- positive bacterial cell wall components. Immunity 1999, 1:443-451.
18. Wiersinga W.J., van der Poll T. Is the septic response good or bad?. Curr Infect Dis Rep 2007, 9:366-373.
19. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
20. Vasselon T., Detmers P.A. Toll receptors: a central element in innate immune responses. Infect Immun 2002, 70:1033.
21. Lorenz E., Mira J.P., Cornish K.L., et al. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000, 68:6398-6401.
22. Lorenz E., Mira J.P., Frees K.L., et al. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162:1028-1032.
23. Haveman J.W., Muller Kobold A.C., Tervaert J.W., et al. The central role of monocytes in pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth J Med 1999, 55(3):132-141.
24. Dinarello C.A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997, 112:321S-329S.
25. Wiersinga W.J., Levi M., van der Poll T. Coagulation in sepsis. Mechanisms of sepsis-induced organ dysfunction and recovery 2007, vol. 44:273-285. Springer-Verlag, Heidelberg (Germany). J.L. Vincent (Ed.).
26. Ward P.A. The dark side of C5a in sepsis. Nat Rev Immunol 2004, 4(2):133-142.
27. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118:503-508.
28. Cavaillon J.M., Adib-conquy M., Fitting C., et al. Cytokine cascade in sepsis. Scand J Infect Dis 2003, 35:535-544.
29. Philippart F., Cavaillon J.M. Sepsis mediators. Curr Infect Dis Rep 2007, 9(5):358-365.
30. Annane D., Bellissant E., Cavaillon J.M. Septic shock. Lancet 2005, 365:63-78.
31. Ley K., Laudanna C., Cybulsky M.I., et al. Getting to the site of inflammation: the leucocyte adhesion cascade updated. Nat Rev Immunol 2007, 7:678-689.
32. Casey L.C., Balk R.A., Bone R.C. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993, 119:771-778.
33. Fisher C.J.J., Opal S.M., Dhainaut J.F., et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993, 21:318-327.
34. Qiu G., Gribbin E., Harrison K., et al. Inhibition of gamma interferon decreases bacterial load in peritonitis by accelerated peritoneal fibrin deposition and tissue repair. Infect Immun 2003, 71:2766-2774.
35. Moreno S.E., Alves-Filho J.C., Alfaya T.M., et al. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J Immunol 2006, 177:3218-3224.
36. Hochholzer P., Lipford G.B., Wagner H., et al. Role of interleukin-18 (IL-18) during lethal shock: decreased lipopolysaccharide sensitivity but normal superantigen reaction in IL-18-deficient mice. Infect Immun 2000, 68:3502-3508.
37. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
38. Calandra T., Spiegel L.A., Metz C.N., et al. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc Natl Acad Sci U S A 1998, 95:11383-11388.
39. Roger T., David J., Glauser M.P., et al. MIF regulates innate immune response through modulation of Toll-like receptor 4. Nature 2001, 414(6866):920-924.
40. Calandra T., Bernhagen J., Metz C.N., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.
41. Flaster H., Bernhagen J., Calandra T., et al. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007, 21:1267-1280.
42. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871.
43. Oppert M., Schindler R., Husung C., et al. Low dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005, 33:2457-2464.
44. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
45. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573.
46. Lotze M.T., Tracey K.J. High mobility group box 1 protein (hmgb1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
47. Yang H., Wang H., Tracey K.J. HMG-1 rediscovered as a cytokine. Shock 2001, 15:247-253.
48. Wang H., Liao H., Ochani M., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10:1216-1221.
49. Weaver C.T., Hatton R.D., Mangan P.R., et al. Il-17 family cytokines and the expanding diversity of effector t-cell lineages. Annu Rev Immunol 2007, 25:821-852.
50. Bouchon A., Dietrich J., Colonna M. Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000, 164:4991-4995.
51. Gibot S., Kolopp-Sarda M.N., Bene M.C., et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004, 200:1419-1426.
52. Bouchon A., Facchetti F., Weigand M.A., et al. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.
53. Adib-Conquy M., Goulenok M., Laurent C., et al. Enhanced plasma levels of soluble triggering expressed on myeloid cells-1 and procalcitonin after cardiac surgery and cardiac arrest in the absence of infection. Shock 2007, 28(4):406-410.
54. Haeney M.R. The role of the complement cascade in sepsis. J Antimicrob Chemother 1998, 41:s41-s46.
55. Huber-Lang M.S. Complement-induced impairment of innate immunity during sepsis. J Immunol 2002, 169:3223-3231.
56. Nakae H. Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol 1994, 84:189-195.
57. Rittirsch D., Flierl M.A., Nadeau B.A., et al. Functional role for C5a receptors in sepsis. Nat Med 2008, 14(5):551-557.
58. Riedemann N.C. Regulatory role of c5a on macrophage migration inhibitory factor release from neutrophils. J Immunol 2004, 173:1355-1359.
59. Gerard C. Complement c5a in the sepsis syndrome- too much of a good thing?. N Engl J Med 2003, 348:167-169.
60. Huber-Lang M. Role of c5a in multiorgan failure during sepsis. J Immunol 2001, 166:1193-1199.
61. Solomkin J.S., Jenkins M.K., Nelson R.D., et al. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery 1981, 90:319-327.
62. Riedemann N.C., Guo R.F., Laudes I.J., et al. C5a receptor and thymocyte apoptosis in sepsis. FASEB J 2002, 16:887-888.
63. Muhlfelder T.W., Niemetz J., Kreutzer D., et al. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest 1979, 63:147-150.
64. Niederbichler A.D., Hoesel L.M., Westfall M.V., et al. An essential role for complement c5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 2006, 203:53-61.
65. Renckens R., Roelofs J.J., Florquin S., et al. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 2006, 176:3735-3741.
66. Yassen K.A., Galley H.F., Webster N.R. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001, 56:729-732.
67. Frick I.M., Bjorck L., Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007, 98:497-502.
68. Fink M.P. Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis. J Antimicrob Chemother 1998, 41(Suppl A):81-94.
69. Mozes T., Zijlstra F.J., Heiligers J.P.C. Interactions between platelet activating factor and eicosanoids during endotoxic shock in anaesthetized pigs. Mediators Inflamm 1992, 1:183-190.
70. Gomes R.N., Layne M.D., Carvajal I.M., et al. Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock 2006, 26:41-49.
71. Pajkrt D., Doran J.E., Koster F., et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996, 184:1601-1608.
72. Imai T., Fujita T., Yamazaki Y. Beneficial effects of apolipoprotein A-I on endotoxemia. Surg Today 2003, 33:684-687.
73. Kengatharan K.M., De Kimpe S.J., Thiemermann C. Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock. Br J Pharmacol 1996, 119:1411-1421.
74. Benjamin C.F., Silva J.S., Fortes Z.B., et al. Inhibition of leukocyte rolling of nitric oxide during sepsis leads to reduced migration of active microbicidal neutrophils. Infect Immun 2002, 70:3602-3610.
75. Han X., Fink M.P., Uchiyama T., et al. Increased iNOS activity is essential for pulmonary epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L259-L267.
76. Evans T., Carpenter A., Silva A., et al. Inhibition of nitric oxide synthase in experimental gram-negative sepsis. J Infect Dis 1994, 169:343-349.
77. López A., Lorente J.A., Steingrub J., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004, 32:21-30.
78. Hotchkiss R.S., Coppersmith C.M., Karl I.E. Prevention of lymphocyte apoptosis-a potential treatment of sepsis. Clin Infect Dis 2005, 41(S7):S465-S469.
79. Borovikova L.V., Ivanova S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
80. Wang H., Yu M., Ochani M., et al. Nicotinic acetylcholine receptor [alpha]7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
81. Levi M., Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592.
82. Esmon C.T. The impact of the inflammatory response on coagulation. Thromb Res 2004, 114:321-327.
83. Levi M., de Jonge E., van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 2004, 36:41-49.
84. Esmon C.T. The protein C pathway. Chest 2003, 124:S26-S32.
85. Levi M., van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007, 11:S3.
86. Faust S.N., Levin M., Harrison O.B., et al. Dysfunction of endothelial protein C activation in meningococcal sepsis. N Engl J Med 2001, 345(6):408-416.
87. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
88. Ely E.W., Laterre P.F., Angus D.C., et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12-19.
89. Abraham E., Laterre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341.
90. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomized controlled trial. Lancet 2007, 369(9564):836-843.
91. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving sepsis campaign management guidelines committee (2004) surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873.
92. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
93. Keh D., Boehnke T., Weber-Cartens S., et al. Immunologic and hemodynamic effects of " low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003, 167:512-520.
94. Laupland K.B., Kirkpatrick A.W., Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007, 35(12):2686-2692.
95. Alejandria M.M., Lansang M.A., Dans L.F., et al. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002, 1. CD001090.
96. Berlot Giorgio, Bacer Barbara, Piva Marco, et al. Immunoglobulins in sepsis. Adv Sepsis 2007, 6(2):41-46.
97. Bone R.C., Balk R.A., Fein A.M., et al. A second large controlled study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 sepsis study group. Crit Care Med 1995, 23:994-1006.
98. Ziegler E.J., Fischer C.J., Sprung C.L., et al. Treatment of gram-negative bacteremia and shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A sepsis study group. N Engl J Med 1991, 324:429-436.
99. Reinhart K., Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001, 29:S121-S125.
100. Fischer C.J., Dhainaut J.F., Opal S.M., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra sepsis syndrome study group. JAMA 1994, 271:1836-1843.
101. Vincent J.L., Sun Q., Dubois M.J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34:1084-1093.